Cigna's Specialty Pharmacy Leadership Expected to Drive Long-Term EPS Growth, Analyst Says
Cigna's Specialty Pharmacy Leadership Expected to Drive Long-Term EPS Growth, Analyst Says
Piper Sandler has initiated coverage on Cigna Corporation (NYSE:CI), a diversified managed care and healthcare delivery organization specializing in commercial insurance markets and pharmacy services.
派杰投资已开始覆盖范围涵盖商业保险市场和药房服务的综合医疗保健和医疗保障提供者Cigna Corporation（NYSE：CI）的评级。
The analyst writes, "We believe Cigna has a unique and defensible leadership position in the fast-growing specialty pharmacy market which, together with the company's insurance segment and core PBM business, should support LT-adjusted EPS growth at a 10-14% CAGR."
分析师写道：“我们认为Cigna在快速增长的特殊药房市场上拥有独特而具有竞争力的领导地位，此外，公司的保险业务和核心PBM业务应支持LT调整后的EPS增长率在10-14%之间。”
Related: Cigna Crushes Q1 Estimates: Revenue Soars With Evernorth's Explosive Growth.
相关新闻: 吉利德的 Trodelvy 在普通膀胱癌最常见类型的后期研究中未能达到主要目标。Cigna冲破Q1预期：随着Evernorth的爆炸式增长，营业收入飙升。
The company's Cigna Healthcare and Evernorth Health Services businesses complement one another and empower Cigna to continue delivering premium adjusted EPS growth against the LT target of 10-14% per year, the Piper analyst writes.
该公司的Cigna Healthcare和Evernorth Health Services业务互补，并使Cigna能够继续实现针对每年10-14%的LT目标的优质调整后的EPS增长，Piper分析师写道。
Cigna grew adjusted EPS at a 13%+ CAGR from 2013-2023, and the company is expected to maintain its track record of consistent execution against industry-leading earnings growth targets over the next decade.
Cigna从2013年至2023年以13%+的CAGR增长了调整后的EPS，预计未来十年公司将保持持续执行行业领先盈利增长目标的记录。
Piper adds, "We believe CI will focus on organic earnings growth until we know the outcome of the 2024 presidential election and get a better understanding of the antitrust/ MA regime for the next 4 years."
Piper补充道：“我们认为（CI）将专注于有机盈利增长，直到我们知道2024年总统大选的结果，并更好地了解未来4年的反垄断/ MA制度。”
Piper initiates with an Overweight rating and a price target of $400.
Piper发起超配评级，并将目标价定为400美元。
A 12.5x multiple is appropriate as it assigns an in-line/slight-premium multiple to the comp group, which Piper writes is justified by Cigna's above-average EPS CAGR.
12.5倍的倍数是适当的，因为它为竞争集团分配了一个与之相符的略高倍数，Piper写道，这是由Cigna高于平均EPS CAGR所证明的。
The analyst also writes that selling the medicare advantage business to HCSC will be a positive catalyst for Cigna when it closes in the first quarter of 2025.
该分析师还写道，将医疗保险业务出售给HCSC将成为Cigna的积极催化剂，该交易预计在2025年第一季度结束。
Piper says Cigna's strong position in the $400 billion specialty market is encouraging. While many are tackling the drug pricing crisis, Cigna is at the forefront.
Piper表示，Cigna在4000亿美元的特殊市场中的强劲地位令人鼓舞。虽然许多人正在解决药品定价危机，但Cigna处于最前沿。
Specialty services drive growth for Evernorth, which is supported by Cigna's transparent PBM business. We are confident in Evernorth's 5-8% long-term growth forecast.
特殊服务推动Evernorth的增长，其由Cigna透明的PBM业务支持。我们对Evernorth的长期增长预测为5-8%充满信心。
Price Action: CI shares are down 0.41% at $337.41 at the last check on Wednesday.
价格行动：CI股价周三最后一次检查时下跌0.41％至337.41美元。
Photo via Shutterstock
图片来自shutterstock。